20:46 , Oct 19, 2018 |  BioCentury  |  Finance

Taiho ups its stakes

After bumping up its evergreen fund from $50 million to $300 million, Taiho Ventures LLC plans to increase its stakes in its portfolio companies. The strategic venture arm of Taiho Pharmaceutical Co. Ltd. launched in...
18:26 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Taiho Ventures increases investment pool to $300M

Taiho Ventures LLC increased its investment pool to $300 million from $50 million. The firm said it will focus the additional funds on oncology startups with drug discovery capabilities or unique platform technologies. Taiho Pharmaceutical...
20:55 , Oct 16, 2018 |  BC Extra  |  Financial News

Taiho Ventures ups investments to $300M, to focus on oncology

Taiho Ventures LLC increased its investment pool to $300 million from $50 million. Taiho Ventures said it will focus the additional funds on oncology startups with drug discovery capabilities or unique platform technologies. Taiho Pharmaceutical...
17:32 , Oct 12, 2018 |  BC Week In Review  |  Clinical News

FDA approves Leadiant therapy for ADA-SCID

Leadiant Biosciences Inc. said FDA approved Revcovi elapegademase-lvlr (EZN-2279) to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency. Approval of the pegylated recombinant adenosine deaminase enzyme replacement therapy is based on two...
19:56 , Oct 8, 2018 |  BC Extra  |  Company News

FDA approves Leadiant therapy for ADA-SCID

Leadiant Biosciences Inc. said FDA approved Revcovi elapegademase-lvlr (EZN-2279) to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency. Approval of the pegylated recombinant adenosine deaminase enzyme replacement therapy is based on two...
18:24 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Kyowa's KW-6356 improves motor symptoms in Phase IIa for early PD

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) said low- and high-dose oral KW-6356 both improved motor symptoms compared with placebo in a Phase IIa trial in 168 patients with early Parkinson's disease who had not received...
06:27 , Aug 10, 2018 |  BC Week In Review  |  Company News

China Medical gains rights to Can-Fite's ADORA3 agonists

CMS Medical Venture Investment Ltd. gained rights to develop and commercialize piclidenoson (CF101) and namodenoson (CF102) in Taiwan and China, including Hong Kong and Macau, from Can-Fite BioPharma Ltd. (Tel Aviv:CFBI; NYSE-A:CANF). Can-Fite received $2...
16:14 , Jul 20, 2018 |  BC Week In Review  |  Company News

Taiho exercises option for AB928

Taiho Pharmaceutical Co. Ltd. (Tokyo, Japan) exercised an option to develop and commercialize AB928 from cancer company Arcus Biosciences Inc. (NYSE:RCUS) in Japan and other Asian territories, excluding China. Arcus will receive an option exercise...
19:01 , Jun 22, 2018 |  BC Week In Review  |  Financial News

Oncology play iTeos raises $75M, outlines clinical plans

iTeos Therapeutics S.A. (Gosselies, Belgium) raised $75 million on June 19 in a series B round led by MPM Capital. Also participating in the round were HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI...
19:04 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture studies suggest inhibiting adenosine kinase, DCK or SLC29A1 could help treat...